Navigation Links
Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404

LONDON and FLORENCE, Italy - 8 March 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces positive initial findings from its second, confirmatory phase II trial of AS1404 in non-small cell lung cancer.

This 30-patient trial tested an 1800 mg/m2 dose of AS1404 in combination with carboplatin and paclitaxel chemotherapy. Investigators reported a response rate of 50%. A further 43% of patients showed disease stabilisation, while only 7% had progressive disease as their best response. Addition of AS1404 to chemotherapy was well-tolerated despite the use of a dose 50% higher than that used in previous combination studies.

The data are included in a presentation made today at the Tumor Microenvironment meeting in Florence, Italy, by Antisoma's Chief Medical Officer, Dr Gary Acton. Further data from the trial, including time to progression and survival findings, are expected during the second half of this year.

An earlier randomised controlled phase II study in lung cancer showed a 5-month increase in median survival when 1200 mg/m2 AS1404 was added to carboplatin and paclitaxel. Initial data from other controlled phase II trials in ovarian and prostate cancers have shown increased response rates with addition of AS1404 to standard chemotherapy.

Dr Mark McKeage of the University of Auckland, New Zealand, a key investigator in both AS1404 lung cancer studies, said: "The high response rate and favourable tolerability profile in this study support earlier data suggesting that AS1404 has real potential as a novel therapy for lung cancer."

Glyn Edwards, CEO of Antisoma, added: "AS1404 now draws support from four phase II studies across three different cancers, an excellent position to be in as we prepare the drug for phase III trials."

Enquiries: Daniel Elger, Director of Communications +44 (0)7909 915 068 Antisoma plc

Mark Court/Lisa Baderoon/
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Data supporting three Antisoma programmes presented at AACR
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
8. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
9. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma plc Second lung cancer trial adds positive data
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, Inc., ... announced today that Eli Diamond , MD, ... Center (MSK), presented clinical data from an ongoing ... monitoring platform for the determination of oncogene mutational ... biopsy.  The results were presented to both treating ...
(Date:10/1/2014)... MARCOS, Texas , Oct. 1, 2014 /PRNewswire/ ... it is scaling volume production of photoactive quantum ... power technologies . While offering numerous advantages for ... of producing large quantities of quantum dots with ... until now kept them from commercial utilization and ...
(Date:10/1/2014)... Oct. 1, 2014  CVS Health is thanking its ... role in changing the way health care is delivered ... the Company,s retail pharmacies, mail service pharmacies and specialty ... our company name to CVS Health to reflect our ... the innovations needed to shape the future of health," ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... 2012 i-Path Media LLC, a pharmaceutical marketing ... with their clients, received national certification as a ... Organization-New York Certification Committee, a regional certifying partner ... WBENC,s national standard of certification is ...
... Jan. 16, 2012  Palatin Technologies, Inc. (NYSE Amex: ... targeted, receptor-specific peptide therapeutics for the treatment of ... potential, today announced that Dr. Carl Spana, President ... Noble Financial Capital Markets, Eighth Annual Equity Conference.  ...
Cached Medicine Technology:Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets' Eighth Annual Equity Conference 2
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... NJ (PRWEB) October 01, 2014 Diet Doc ... their intentions to lose weight and their dieting attempts could ... fatty foods. Including hormone diet treatments into their ... allows patients to see fast and effective weight loss results, ... begin forming healthy habits to maintain their weight for the ...
(Date:10/1/2014)... Scientists at the University of Western Australia ... system proteins has the power to knock out mesothelioma ... the new study on their website. Click here ... the UWA School of Pathology and Laboratory Medicine administered ... mesothelioma with promising results. , “A timed triple ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Nordic ... benefit a very special cause. The campaign—“Buy One ... for Paws for Veterans, a nonprofit organization that ... also rescuing shelter dogs that would otherwise face ... featured products will support monthly donations of Nordic ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... , ATLANTA and PHILADELPHIA, ... Technology, collaborating with pediatric cardiologists and surgeons at The ... virtual surgery that allows heart surgeons to view the ... cardiac magnetic resonance images of a patient,s specific anatomy, ...
... , , NIAGARA ... Pacific Corporation,s (Nasdaq: APFC ) wholly-owned in-space propulsion ... monopropellant engines, with a 30+ year history of successful space ... NASA,s Lunar Reconnaissance Orbiter (LRO) and Lunar Crater Observation and ...
... ... Technology for its Passport Assets Application Enabling Its Customers to Improve System Efficiency, Improve ... ... ASAP Systems today announced the release of its mobile RFID technology for their ...
... , , , ... device franchise, announced today the launch of eMed-Alert, a next-generation personal assistance ... in an emergency. With more than 11 million Americans age 65 ... their independence. , , "As baby ...
... , SOMERSET, N.J., Aug. 11 ... healthcare and administrative staffing services, will announce its third quarter financial results ... before the market opens. TeamStaff will host a conference call for ... Interested parties may participate in the call by dialing (877) ...
... PRINCETON, N.J., Aug. 11 Ranbaxy Pharmaceuticals Inc. (RPI), a ... that RLL has received final approval from the U.S. Food ... 25 mg (base), and 50 mg (base). The Office ... the Ranbaxy formulations to be bioequivalent and have the same ...
Cached Medicine News:Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 2Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 3Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 4Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 5Health News:AMPAC-ISP Engines Support Key NASA Lunar Missions 2Health News:ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility 2Health News:ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility 3Health News:World's First Emergency Medical Device Franchise Launches eMed-Alert 2Health News:World's First Emergency Medical Device Franchise Launches eMed-Alert 3Health News:TeamStaff, Inc. To Announce Third Quarter Results 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 3Health News:Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
Medicine Products: